Gilead Sciences, Inc.
Recent
price
P/E
ratio
div
yld
2.29%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.
Company News
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Gilead's pill succeeds in mid-stage bowel disease trial
Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $468,660.00 in Stock
Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $468,660.00 in Stock
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
The Big 3: MRK, GILD, XOM
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying